Comparison · NCT00490451-sae
LY573636 Target Cmax 420 µg/mL vs LY573636 Target Cmax 360 µg/mL: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LY573636 Target Cmax 420 µg/mL vs LY573636 Target Cmax 360 µg/mL: serious adverse events. Trial comparisons, record NCT00490451-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00490451-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.365 | 0.257 | 0.489 | wilson | |
| Risk in group 2 | 0.263 | 0.15 | 0.42 | wilson | |
| Risk difference, group 1 minus group 2 | 0.102 | -0.0885 | 0.27 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.39 | 0.743 | 2.59 | log | |
| Odds ratio, group 1 over group 2 | 1.61 | 0.664 | 3.9 | log | |
| Number needed to harm, for one more participant with a serious adverse event on LY573636 Target Cmax 420 µg/mL than on LY573636 Target Cmax 360 µg/mL | 9.81 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LY573636 Target Cmax 420 µg/mL | LY573636 dose is dependent on participant's height, weight, and gender to target maximum concentration (Cmax) of 420 micrograms/milliliter (µg/mL) and is administered intravenously every 21- or 28-day cycle until disease progression or other criteria for participant discontinuation are met. | 23 | 63 | EG000 |
| Group 2 | LY573636 Target Cmax 360 µg/mL | LY573636 dose is dependent on participant's height, weight, and gender to target maximum concentration (Cmax) of 360 micrograms/milliliter (µg/mL) and is administered intravenously every 21- or 28-day cycle until disease progression or other criteria for participant discontinuation are met. | 10 | 38 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
- NCT number
- NCT00490451
- Phases
- PHASE2
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- LY573636-sodium
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2018-05-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00490451?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00490451-sae